Fluidigm, a US-based provider of integrated fluidic circuits for the life sciences market, sold more shares than expected at the bottom of its planned price range in its Nasdaq flotation.
Fluidigm raised $75m at $13.50 per share by selling 5.6 million shares, with a further 833,750 available if demand is strong enough for its investment banks Deutsche Bank and Piper Jaffray, according to its regulatory filing.
The company originally filed for an IPO in early 2008, but cancelled the offering later that same year and has reportedly raised more than $200m from investors.
EuclidSR Partners, a corporate venturing joined venture including drugs company GlaxoSmithKline, has 6.6% and will be diluted to 4.8% after the IPO.
The Singapore government owns 13.7% pre-IPO, mutual fund manager Fidelity has 10.9%,while venture capital firms Versant Ventures, InterWest and Alloy Ventures own stakes. Lilly ventures, the corporate venturing unit of drugs company Eli Lilly, General Electric, Lehman Brothers, Piper Jaffray have also invested.